# Paracor Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paracor-medical

- Industry: Medical Devices & Equipment
- Headquarters: Sunnyvale, US
- Website: www.paracormedical.com
- Total disclosed funding: $94M
- Latest round: Series D (Sep 17, 2007)
- Investors on record: 11

## About

Paracor Medical is a laboratory equipment provider focused on delivering advanced solutions tailored for diverse scientific and medical sectors, facilitating precise research and testing.Founded in 1999 and headquartered in Sunnyvale, US, Paracor Medical specializes in laboratory equipment. The company has executed a total of 6 deals and recently completed a SERIES D funding round, raising USD 0.230 mn, which matches the total amount raised of USD 0.230 mn. Key investors in this round included De Novo Ventures, Delphi Ventures, FirstMark Capital, and InterWest Partners. The founder's details are not specified, and there are no known subsidiaries or pivots in strategy.Paracor Medical specializes in providing a diverse array of laboratory equipment designed to meet the needs of various scientific and medical sectors. Their core offerings include Microplate Readers, Analytical Balances, Laboratory Centrifuges, Spectrophotometers, Electrosurgical Units, and Sterilizers & Autoclaves, catering to industries such as pharmaceuticals, education, food and beverage, chemicals, and research institutions. These products support complex lab processes, facilitating accurate research outcomes and are utilized across North America, Europe, and Asia-Pacific.Paracor Medical's revenue model relies on direct sales of high-quality laboratory equipment to clients, including research institutions, hospitals, and educational facilities. Transactions occur on a business-to-business (B2B) basis through direct orders on the company’s website or via sales representatives. Notable products like the BioTek Synergy H1 Microplate Reader and Eppendorf Centrifuge 5810 R exemplify their offerings, with pricing reflective of advanced technology. Promotional strategies also aid in revenue generation.Paracor Medical is currently focusing on the development of new laboratory equipment, with plans for specific product launches expected in the near future. The company aims to expand its presence in international markets, particularly targeting regions in Asia-Pacific, with anticipated entry by the end of 2024. Recent funding from the SERIES D round will support these initiatives, as Greenspring Associates has realized its stake in the firm.

## Funding rounds

- Series D, Sep 17, 2007, $0.2M — Delphi Ventures, InterWest Partners, De Novo Ventures, FirstMark Capital
- Series D, Jun 22, 2007, $44M — Alta Partners, Delphi Ventures, InterWest Partners, Greenspring Associates, Aberdare Ventures, De Novo Ventures, Saratoga Ventures, FirstMark Capital, Palo Alto Investors
- Series C, Jun 10, 2004, $31M — Alta Partners, Delphi Ventures, InterWest Partners, De Novo Ventures, Pequot Ventures
- Series B, Jun 26, 2002, $16M — InterWest Partners, De Novo Ventures, FirstMark Capital
- Series A, Jun 1, 2001, $3M — De Novo Ventures, RWI Ventures

## Investors

- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series A, Series B, Series C, Series D
- RWI Ventures (https://capitalatlas.ai/funds/rwi-ventures) — Series A
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series B, Series C, Series D
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series B, Series D
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C, Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series C, Series D
- Pequot Ventures (https://capitalatlas.ai/funds/pequot-ventures) — Series C
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series D
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series D
- Saratoga Ventures (https://capitalatlas.ai/funds/saratoga-ventures) — Series D
- Palo Alto Investors (https://capitalatlas.ai/funds/palo-alto-investors) — Series D